Inari competes through specialized, differentiated device design focused on specific procedural workflows rather than broad-platform approaches. The company maintains strong gross margins (88%+) and leverages a growing commercial organization targeting interventional radiologists, cardiologists, and vascular surgeons. Strategic focus centers on clinical evidence generation (PEERLESS study) and geographic/indication expansion to drive adoption and defend against larger competitors entering the space.
Cyborg Score Rationale
Inari demonstrates solid revenue growth (23% YoY in H1 2024), best-in-class gross margins, and differentiated product portfolio addressing underserved vascular disease markets. However, profitability deteriorated in Q3 2024 (GAAP operating loss of $13.6M vs. $2.1M income YoY) due to increased R&D and commercial investments, and competitive pressure from larger, better-capitalized competitors is rising.
Top Insights
Revenue grew 23% in Q1 and Q2 2024 ($143.2M and $146M respectively), with Q3 2024 reaching $153M and 21% YoY growth, demonstrating consistent mid-20% expansion
Profitability declined sharply: Q3 2024 GAAP operating loss of $13.6M vs. $2.1M operating income in Q3 2023, signaling margin pressure from aggressive commercial expansion and R&D investments
Successfully launched VenaCore (June 2024), a purpose-built device for acute and chronic deep vein thrombosis treatment, representing portfolio expansion into large market opportunity
PEERLESS clinical study on track for presentation in H2 2024, critical for establishing clinical evidence and differentiating against larger competitors entering the space
Named Competitors
Thrombectomy and Vascular Intervention Portfolio — Large diversified medical device company with broad thrombectomy and neurovascular portfolio
Vascular and Thrombectomy Systems — Diversified medtech with expanding peripheral vascular and VTE intervention offerings
Thrombectomy and Neurovascular Devices — Specialized medtech focused on thrombectomy and neurointerventional procedures
Recent Developments
(June 2024) Commenced full commercial launch of VenaCore for acute and chronic DVT treatment
(April 2024) Generated $143.2M in Q1 2024 revenue, up 23.3% YoY
(July 2024) Reported Q2 2024 revenue of $146M, up 23% YoY, with strong adoption across VTE and Emerging Therapies segments
(October 2024) Announced Q3 2024 revenue of $153M, up 21% YoY, but GAAP operating loss widened to $13.6M
Open the full interactive Inari Medical, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.